Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource reported that its daily average number of contract processing orders in December 2025 rose year-on-year to 48.0, driven mainly by growth in hybrid orthopedics and aesthetic medicine despite declines in self-funded orthopedics and OB&GYN orders. By department, monthly orders for self-funded orthopedics fell 3.8% to 708 while hybrid orthopedics increased 7.7% to 586, with the company attributing the hybrid segment’s growth to targeted measures at key medical institutions and noting that its enhanced business support for medical corporations continues even as some order volumes soften, underscoring a shift in demand mix within its blood-derived product services portfolio.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen455.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the medical and healthcare sector, focusing on contract processing services for blood-derived products used across specialties such as orthopedics, obstetrics and gynecology (OB&GYN), and aesthetic medicine in Japan. The company supports both self-funded and hybrid orthopedic practices and provides business support services to strengthen the organizational structures of medical corporations using its offerings.
Average Trading Volume: 100,796
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.34B
Learn more about 4880 stock on TipRanks’ Stock Analysis page.